| 主权项 |
1. A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein in Formula I: R1 is selected from the group consisting of a NR1AR1B, —X1R—NR1AR1B, —X1R—OR1A, 5-10 membered heteroaryl ring comprising 1 to 4 nitrogen atoms and 4-10 membered C-linked heterocycloalkyl comprising 1 to 3 nitrogen atoms; R1A and R1B are each independently selected from the group consisting of hydrogen, C1-8 alkyl, —C(═Y1)ORR1C, —C(═Y1)RR1C, —C(═Y1)N(RR1C)2, —(X1R)0-1Rx, and C1-8 alkoxy; or R1A and R1B are optionally combined to form a 4-10 membered heterocyclic ring optionally comprising 1 to 3 additional heteroatoms selected from N, O and S as ring vertices; RR1C is selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C2-7 heterocycloalkyl, phenyl, benzyl and 5-6 membered heteroaryl; X1R is independently selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and C2-4 alkynylene, wherein X1R is optionally substituted with one or more groups selected from oxo and thioxo; Y1 is independently O or S; R″ is independently selected from the group consisting of 6-10 membered aryl, 5-10 membered heteroaryl, C3-8 cycloalkyl and C2-7 heterocycloalkyl; and wherein R1 is optionally further substituted with from 1 to 5 substituents independently selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl-(X1R)0-1—, C3-8 heterocycloalkyl-(X1R)0-1—, 6-10 membered aryl-(X1R)0-1—, 5-10 membered heteroaryl-(X1R)0-1—, F, Cl, Br, I, —CN, —NO2, (X1R)0-1NRR1aRR1b, —(X1R)0-1ORR1a, —(X1R)0-1SRR1a, —(X1R)0-1N(RR1a)C(═Y1)ORR1c, —(X1R)0-1OC(═O)N(RR1a)(RR1b), —(X1R)0-1N(RR1a)C(═O)N(RR1a)(RR1b), —(X1R)0-1C(═O)N(RR1a)(RR1b), —(X1R)0-1N(RR1a)C(═O)RR1b, —(X1R)0-1C(═O)ORR1a, —(X1R)0-1OC(═O)RR1a, —(X1R)0-1—P(═O(RR1a)(ORR1b), —(X1R)0-1S(O)1-2RR1c, —(X1R)0-1S(O)1-2N(RR1a)(RR1b), —(X1R)0-1N(RR1a)S(O)1-2N(RR1a)(RR1b) and —(X1R)0-1N(RR1a)S(O)1-2(RR1c); RR1a and RR1b are each independently selected from the group consisting of hydrogen, C1-8alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-8alkyl, C3-8 cycloalkyl-C1-8alkoxy, tetrahydronapthalene, phenyl, phenyl-C1-8 alkyl, phenyl-C1-8 alkoxy, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-8 alkyl, 5-6 membered heteroaryl-C1-8 alkoxy, 3-7 membered heterocycloalkyl, 3-7 membered heterocycloalkyl-C1-8 alkyl, 3-7 membered heterocycloalkyl-C1-8 alkoxy; or RR1a and RR1b together with a nitrogen to which they are attached form a morpholino, piperidino, or piperazinyl ring, wherein said ring is optionally substituted with one or more groups independently selected from C1-8alkyl, halo, hydroxy, C1-8 alkylamino, C1-8 dialkylamino, C1-8 haloalkyl and C1-8 hydroxyalkyl; RR1c is selected from the group consisting of C1-8alkyl, C1-8haloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-8alkyl, C3-8 cycloalkyl-C1-8alkoxy, tetrahydronapthalene, phenyl, phenyl-C1-8 alkyl, phenyl-C1-8 alkoxy, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-8 alkyl, 5-6 membered heteroaryl-C1-8 alkoxy, 3-7 membered heterocycloalkyl, 3-7 membered heterocycloalkyl-C1-8 alkyl, 3-7 membered heterocycloalkyl-C1-8 alkoxy; RN is hydrogen, C1-4 alkyl or C1-4 haloalkyl; D1 is N or C(RD1); D3 is N or C(RD3); RD1, RD2, RD3 and RD4 are each independently selected from the group consisting of H, F, Cl, Br, I, —CN, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, C3-8 cycloalkyl, C2-7 heterocycloalkyl, phenyl and 5-6 membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O and S, wherein said 5-6 membered heteroaryl is further optionally substituted with from 1 to 3 substituents selected from F, Cl, Br, I, —CN, C1-4 alkyl, C1-4 haloalkyl and C1-4 alkoxy; L is a linker selected from the group consisting of C1-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, and C1-4 heteroalkylene, wherein L is optionally substituted with from 1 to 3 substituents independently selected from the group consisting of ═O, C1-4 alkyl, C1-4 haloalkyl and C1-4 acyl; the subscript m represents the integer 0 or 1; X1 and X2 are each independently selected from the group consisting of absent, —O—, —S—, —S(O)—, —S(O)2—N(H)—, and —N(Rx1)— wherein Rx1 is C1-8alkyl, C1-8 acyl or —S(O)2(C1-8 alkyl), and wherein if the subscript m is 0 then one of X1 or X2 is absent; the subscript n is an integer from 0 to 5; A ring represents a 6-10 membered aryl or a 5-10 membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O and S; RA at each occurrence, is independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl-(XRA)0-1, C3-8 halocycloalkyl-(XRA)0-1, C1-8 cyanoalkyl, C1-8 hydroxyalkyl, C3-8 cycloalkyl-C1-8alkyl, F, Cl, Br, I, —CN, —NO2, C2-9 heterocycloalkyl-(XRA)0-1—, C6-10 membered aryl-(XRA)0-1—, 5-6 membered heteroaryl-(XRA)0-1—, —(XRA)0-1NRA1RA2, —(XRA)0-1ORA1, —(XRA)0-1SRA1, —(XRA)0-1N(RA1)C(═O)ORA3, —(XRA)0-1C(═O)N(RA1)(RA2), —(XRA)0-1N(RA1)C(═O)N(RA1)(RA2), —(XRA)0-1C(═O)N(RA1)(RA2), —(XRA)0-1N(RA1)C(═)RA2, —(XRA)0-1C(═)RA1, —(XRA)0-1C(═O)ORA1, —(XRA)0-1OC(═O)RA1, —P(═O)(ORA1)(ORA2), —(XRA)0-1S(O)1-2RA3, —(XRA)0-1S(O)1-2N(RA1)(RA2), —(XRA)0-1N(RA1)S(O)1-2N(RA1)(RA2) and —(XRA)0-1N(RA1)S(O)1-2(RA3); each XRA is independently selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and C2-4 alkynylene, which C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and C2-4 alkynylene is optionally substituted with one or more groups selected from oxo and thioxo; RA1 and RA2 are independently selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-8alkyl, C3-8 cycloalkyl-C1-8alkoxy, tetrahydronapthalene, phenyl, phenyl-C1-8 alkyl, phenyl-C1-8 alkoxy, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-8 alkyl, 5-6 membered heteroaryl-C1-8 alkoxy, 3-7 membered heterocycloalkyl, 3-7 membered heterocycloalkyl-C1-8 alkyl, 3-7 membered heterocycloalkyl-C1-8 alkoxy; or RA1 and RA2 together with a nitrogen to which they are attached form a morpholino, piperidino, or piperazinyl ring, which ring is optionally substituted with one or more C1-8alkyl, halo, hydroxy, C1-8 haloalkyl, and C1-8 hydroxyalkyl; RA3 is selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-8 alkyl, C3-8 cycloalkyl-C1-8 alkoxy, tetrahydronapthalene, phenyl, phenyl-C1-8 alkyl, phenyl-C1-8 alkoxy, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-8 alkyl, 5-6 membered heteroaryl-C1-8 alkoxy, 3-7 membered heterocycloalkyl, 3-7 membered heterocycloalkyl-C1-8 alkyl, 3-7 membered heterocycloalkyl-C1-8 alkoxy; wherein RA is optionally further substituted with from 1 to 5 substituents independently selected from the group consisting of F, Cl, Br, I, —NH2, —OH, —CN, —NO2, oxo (═O), C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4haloalkyl-C(═O)—, C1-4haloalkyl-S(O)0-2—, C1-4haloalkyl-C(═O)N(H)—, C1-4haloalkyl-N(H)—C(═O)—, (haloalkyl)2N—C(═O)—, C1-4 haloalkyl-OC(═O)N(H)—, C1-4haloalkyl-OC(═O)N(H)—, haloalkyl-N(H)—C(═O)O—, (haloalkyl)2N—C(═O)O—, C1-4 alkylamino, C1-4 dialkylamino, C3-6 cycloalkyl, C3 cycloalkoxy, C2-5 heterocycloalkoxy and tetrahydronaphthalene. |
